Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

XCUR Exicure Inc

0,4581

-0,0159 (-3,35%)

Zuletzt aktualisiert: 17:19:12

Verzögert um 15 Minuten

Form 3 - Initial statement of beneficial ownership of securities

Exicure (NASDAQ:XCUR)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Exicure Charts.

Exicure (NASDAQ:XCUR)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Exicure Charts.

News Exicure Inc

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 16 Mai 2024 (6 Tage vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 16 Mai 2024 (6 Tage vor) • Edgar (US Regulatory)

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
Donnerstag 16 Mai 2024 (6 Tage vor) • Edgar (US Regulatory)

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
Donnerstag 16 Mai 2024 (6 Tage vor) • Edgar (US Regulatory)

Exicure, Inc. Reports Third Quarter 2023 Financial Results
Donnerstag 16 Mai 2024 (6 Tage vor) • Business Wire

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
Mittwoch 15 Mai 2024 (7 Tage vor) • Edgar (US Regulatory)

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
Montag 22 April 2024 (4 Wochen vor) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 6 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 5 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Montag 4 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Montag 5 Februar 2024 (4 Monate vor) • Edgar (US Regulatory)

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
Montag 5 Februar 2024 (4 Monate vor) • Business Wire

Weitere Exicure Inc News-Artikel

Amundi Luxembourg

Orange SA 1.75% maturity...

Societe Generale Effekten

Bristol-Myers Squibb

Ly Russia Dis U

FCF International Qualit...

Vontobel Financial Produ...

iShares MSCI ACWI ex US

BNP Paribas Issuance

BlackRock Institutional ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen